Lexicon Sotagliflozin SOLOIST-WHF Post-Hoc Analysis Shows Consistent Heart Failure Benefit Across Baseline Systolic Blood Pressure at ESC 2026 and JACC: Heart Failure
Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.